1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Augurex Life Sciences, Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management

19 Nov 2024
Admin
News Article

Augurex Life Sciences, Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management

Overview

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, announced that it has formed a nonexclusive agreement with Quest Diagnostics, a leading provider of diagnostic information services, under which Quest will validate and offer a lab-developed test based on the Augurex 14-3-3? (eta) biomarker in the United States.

Quest to Launch New Test Service for Physicians Starting December 2024

Quest intends to begin offering the test service to physicians from its advanced laboratory in San Juan Capistrano, California, by December 2, 2024.
With a physician’s order, patients interested in the test will be able to provide a blood specimen at one of over 2,000 Quest Diagnostics patient service centres in the United States.

The 14-3-3eta test aids in detecting elevated levels of the 14-3-3eta protein, which are specific for rheumatoid arthritis (RA) and linked to more severe disease and joint damage risk.

Words from the CEO: Augurex

“Reintroducing the 14-3-3eta test with Quest Diagnostics is an important step in meeting the evolving needs of RA patients and clinicians,” said Neil Klompas, CEO of Augurex.
“With the increasing recognition of 14-3-3eta as a valuable biomarker in inflammatory diseases, Quest’s reintroduction of this test to physicians in the US will expand access to an important tool for speeding treatment decisions.”

Statement from the Quest Diagnostics

“Our agreement with Augurex builds on our record of innovation in autoimmune disease, which includes being the first US lab provider to introduce a lab-developed test based on the Augurex 14-3-3eta biomarker more than a decade ago. We look forward to reintroducing our 14-3-3eta lab-developed test to physicians later this month,” said James D. Faix, M.D., medical director, immunology and R&D, Quest Diagnostics.

About the Company: Augurex

Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world.